Post-Myocardial Infarction is a new study from Decision Resources, Inc., that examines how the need for better and novel cardioprotective agents to treat post-myocardial infarction (PMI) has created a significant sales opportunity for companies competing in this arena.

  (Photo:  http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )    Statins Remain Dominant as Rosuvastatin Takes the Lead 

The PMI market will experience rapid growth from 2000 to 2005, driven by the launch of AstraZeneca's new "super statin," rosuvastatin (Crestor), which will quickly rival the sales of atorvastatin (Parke-Davis/Pfizer's Lipitor). In 2005, we expect sales of rosuvastatin to reach more than $1 billion, representing 28% of total statin sales for the treatment of PMI.

Novel Therapies Will Have an Impact on PMI Sales

Novel therapies such as Pfizer's avasimibe and Schering-Plough/Merck's ezetimibe/simvastatin combination will enter the field of lipid-lowering drugs and compete with the existing statins. Physicians are optimistic about avasimibe's ability to considerably reduce atherosclerotic lesion area, and we believe that this drug, either alone or in combination with a statin, will be a successful addition to the PMI market.

Bristol-Myers Squibb Re-Emerges on the Market with Omapatrilat

With two ACEIs off patent, Bristol-Myers Squibb will be eager to get back into this market through the launch of the vasopeptidase inhibitor omapatrilat (Vanlev). With pravastatin (Pravachol), Bristol-Myers Squibb already has a presence in the statin field, and it has had success with the antiplatelet agent clopidogrel (Plavix); by adding omapatrilat to its portfolio, Bristol- Myers Squibb becomes one of the largest players in PMI. Similarly, with lovastatin just off patent and simvastatin's patent due to expire in 2005, Merck will be heavily promoting its simvastatin/ezetimibe combination to maintain market share in the lipid-lowering arena.

Post-Myocardial Infarction offers invaluable market intelligence for competing in this arena. This study is part of Cardium, one of six Pharmacor services that evaluate the commercial potential of drugs in research and development.

Decision Resources, Inc., is a world leader in pharmaceutical research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Founded as a subsidiary of Arthur D. Little, Inc., the company has provided strategic information services for 30 years. Visit the Decision Resources Web site at http://www.dresources.com/.

   Contact:    Frank Sama, 781.296.2553 (telephone), 781.296.2550 (fax), or    sama@dresources.com.    In Europe, contact Francoise Bidart, +32.2.351.4082 (telephone),    +32.2.351.2347 (fax), or fbidart@decisionresources.be.    In Japan, contact Makiko Yoshimoto, +81.3.5401.2615 (telephone),    +81.3.5401.2617 (fax), or makiko@bl.mmtr.or.jp.                    MAKE YOUR OPINION COUNT -  Click Here              http://tbutton.prnewswire.com/prn/11690X57582054 

NewsCom: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION AP Archive: http://photoarchive.ap.org/ PRN Photo Desk, 888-776-6555 or 212-782-2840

SOURCE: Decision Resources, Inc.

Contact: Frank Sama of Decision Resources, Inc., +1-781-296-2553, sama@dresources.com